James Quigley analyst MORGAN STANLEY

Currently out of the existing stock ratings of James Quigley, 29 are a HOLD (54.72%), 21 are a BUY (39.62%), 3 are a SELL (5.66%).

James Quigley

Work Performance Price Targets & Ratings Chart

Analyst James Quigley, currently employed at MORGAN STANLEY, has had 45.56% of price targets met with an average potential upside of 13.65%, reached in 151 days on average. Previously, James Quigley worked at JPMORGAN, BERENBERG.

James Quigley has documented 100 price targets and ratings displayed on 9 stocks. The coverage is on Healthcare, Consumer Defensive sectors.

Most recent stock forecast was given on KYMR, Kymera Therapeutics at 27-Oct-2026.

Wall Street Analyst James Quigley

Analyst best performing recommendations are on KYMR (KYMERA THERAPEUTICS).
The best stock recommendation documented was for GLPG (GALAPAGOS NV ADR) on 1/4/2022. The price target of $67 was fulfilled within 24 days with a profit of $12.77 (23.55%), with a performance score of 9.81.

Average potential price target upside

MOR MorphoSys AG ADR GLPG Galapagos NV ADR EVO Evotec SE ADR KYMR Kymera Therapeutics NVO Novo Nordisk A/S NVS Novartis AG ADR LZ LegalZoom.com MO Altria Group GRFS Grifols SA ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 06-Feb-2024

$17

2 years 9 months 15 days ago
(06-Feb-2024)

3/4 (75%)

$12.45 (273.63%)

250

Buy Since 16-Jun-2023

$17

$17

2 years 9 months 16 days ago
(05-Feb-2024)

3/3 (100%)

$-0.27 (-1.56%)

96

Buy Since 16-Jan-2024

2 years 10 months 2 days ago
(19-Jan-2024)

4/7 (57.14%)

$2.7 (41.54%)

490

Buy Since 05-Dec-2023

$8.5

$10

2 years 11 months 16 days ago
(05-Dec-2023)

2/3 (66.67%)

$0.92 (12.14%)

106

Buy Since 05-Dec-2023

$8.5

$10

2 years 11 months 16 days ago
(05-Dec-2023)

3/4 (75%)

$0.92 (12.14%)

253

Show more analysts

Please expand the browser size to see the chart

Which stock is James Quigley most bullish on?

Potential upside of $30.69 has been obtained for KYMR (KYMERA THERAPEUTICS)

Which stock is James Quigley most reserved on?

Potential downside of $9.18 has been obtained for NVO (NOVO NORDISK A/S)

What Year was the first public recommendation made by James Quigley?

On 2018
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?